The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
Open accessAbstract
Oral daily (2.5 mg) and intermittent ibandronate (between-dose interval of >2 months), delivering a similar cumulative exposure, were evaluated in 2946 osteoporotic women with prevalent vertebral fracture. Significant reduction in incident vertebral fracture risk by 62% and 50%, respectively, was shown after 3 years. This is the first study to prospectively show antifracture efficacy for the intermittent administration of a bisphosphonate. Introduction: Bisphosphonates are important therapeutics in postmenopausal osteoporosis. However, they are currently associated with stringent dosing instructions that may impair patient compliance and hence therapeutic efficacy. Less frequent, intermittent administration may help to overcome these deficiencies. This study assessed the efficacy and safety of oral ibandronate administered either daily or intermittently with a dose-free interval of >2 months. Materials and Methods: This randomized, double-blind, placebo-controlled, parallel-group study enrolled 2946 postmenopausal women with a BMD T score ≤ −2.0 at the lumbar spine in at least one vertebra (L1-L4) and one to four prevalent vertebral fractures (T4-L4). Patients received placebo or oral ibandronate administered either daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months). Results and Conclusions: After 3 years, the rate of new vertebral fractures was significantly reduced in patients receiving oral daily (4.7%) and intermittent ibandronate (4.9%), relative to placebo (9.6%). Thus, daily and intermittent oral ibandronate significantly reduced the risk of new morphometric vertebral fractures by 62% (p = 0.0001) and 50% (p = 0.0006), respectively, versus placebo. Both treatment groups also produced a statistically significant relative risk reduction in clinical vertebral fractures (49% and 48% for daily and intermittent ibandronate, respectively). Significant and progressive increases in lumbar spine (6.5%, 5.7%, and 1.3% for daily ibandronate, intermittent ibandronate, and placebo, respectively, at 3 years) and hip BMD, normalization of bone turnover, and significantly less height loss than in the placebo group were also observed for both ibandronate regimens. The overall population was at low risk for osteoporotic fractures. Consequently, the incidence of nonvertebral fractures was similar between the ibandronate and placebo groups after 3 years (9.1%, 8.9%, and 8.2% in the daily, intermittent, and placebo groups, respectively; difference between arms not significant). However, findings from a posthoc analysis showed that the daily regimen reduces the risk of nonvertebral fractures (69%; p = 0.012) in a higher-risk subgroup (femoral neck BMD T score < −3.0). In addition, oral ibandronate was well tolerated. Oral ibandronate, whether administered daily or intermittently with an extended between-dose interval of >2 months, is highly effective in reducing the incidence of osteoporotic fractures in postmenopausal women. This is the first time that significant fracture efficacy has been prospectively shown with an intermittently administered bisphosphonate in the overall study population of a randomized, controlled clinical trial. Thus, oral ibandronate holds promise as an effective and convenient alternative to current bisphosphonate therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J. A., Downs, R. W., Dequeker, J., Favus, M. J., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,276
Self-citationEffect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black, D. M., Thompson, D. E., Bauer, D. C., Ensrud, K., Musliner, T., Hochberg, M. C., Nevitt, M. C., Suryawanshi, S., & Cummings, S. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6953 · Cited by 982
Noninvasive assessment of bone mineral and structure: State of the art
Genant, H. K., Engelke, K., Fuerst, T. P., Glüer, C., Grampp, S., Harris, S. T., Jergas, M. D., Lang, T., Lü, Y., Majumdar, S., et al. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110602 · Cited by 948
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P. D., Woodson, G. C., Yanover, M., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230201 · Cited by 947
Self-citationStorm, T., Thamsborg, G., Steiniche, T., Genant, H. K., & Sørensen, O. H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221803 · Cited by 926
Research works printed but not linked: 4
- Melton, 1991, Long-term fracture risk prediction with bone mineral measurements made at various skeletal sites, J Bone Miner Res, 6, S136
- Kendler, 2002, Patient preference of once weekly or daily administration of alendronate (Fosamax) for osteoporosis: a randomized cross-over study, Osteoporos Int, 13, S32
- Palmisano, 2002, Preference study of alendronate 70 mg once weekly and alendronate 10 mg once daily in postmenopausal women with osteoporosis, Osteoporos Int, 13, S36
- Kiel, 1995, Assessing vertebral fractures. National Osteoporosis Foundation Working Group on Vertebral Fractures, J Bone Miner Res, 10, 518
Cited by
Sorted by citations
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Self-citationOnce-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citationEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C. C., Rizzoli, R., & Reginster, J. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,993
Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
Compston, J. E., McClung, M. R., & Leslie, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32112-3 · Cited by 2,449
An overview and management of osteoporosis
Sözen, T., Özışık, L., & Çalık Başaran, N. (2019) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2016.048 · Cited by 2,262
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4704-5 · Cited by 1,900
Black, D. M., & Rosen, C. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1513724 · Cited by 1,790
Bisphosphonates: Mechanism of action and role in clinical practice
Drake, M. T., Clarke, B. L., & Khosla, S. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1032 · Cited by 1,644
The clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,442
Black, D. M., Schwartz, A. V., Ensrud, K. E., Cauley, J. A., Levis, S., Quandt, S. A., Satterfield, S., Wallace, R. B., Bauer, D. C., Palermo, L., et al. (2006) · JAMA · doi:10.1001/jama.296.24.2927 · Cited by 1,407
Camacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris, S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., et al. (2020) · Endocrine Practice · doi:10.4158/gl-2020-0524suppl · Cited by 1,182
Sambrook, P. N., & Cooper, C. C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68891-0 · Cited by 1,201
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.esgl · Cited by 1,140
Bisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,164
UK clinical guideline for the prevention and treatment of osteoporosis
The National Osteoporosis Guideline Group (NOGG), Compston, J. E., Cooper, A., Cooper, C. C., Gittoes, N. J. L., Gregson, C. L., Harvey, N. C., Hope, S., Kanis, J. А., McCloskey, E. V., et al. (2017) · Archives of Osteoporosis · doi:10.1007/s11657-017-0324-5 · Cited by 865
Prevention and treatment of postmenopausal osteoporosis
Tella, S. H., & Gallagher, J. C. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.09.008 · Cited by 786
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. А., Burlet, N., Cooper, C. C., Delmas, P. D., Reginster, J., Borgström, F., & Rizzoli, R. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0560-z · Cited by 796
Self-citationDenosumab and bisphosphonates: Different mechanisms of action and effects
Baron, R., Ferrari, S., & Russell, R. G. G. (2010) · Bone · doi:10.1016/j.bone.2010.11.020 · Cited by 738
Black, D. M., Reid, I. R., Boonen, S., Bucci-Rechtweg, C., Cauley, J. A., Cosman, F., Cummings, S. R., Hue, T. F., Lippuner, K., Lakatos, P., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1494 · Cited by 700
Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676
Adler, R. A., Fuleihan, G. E., Bauer, D. C., Camacho, P. M., Clarke, B. L., Clines, G. A., Compston, J. E., Drake, M. T., Edwards, B. J.-A., Favus, M. J., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2708 · Cited by 689
UK clinical guideline for the prevention and treatment of osteoporosis
Gregson, C. L., Armstrong, D. J., Bowden, J., Cooper, C., Edwards, J., Gittoes, N. J. L., Harvey, N., Kanis, J., Leyland, S., Low, R., et al. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01061-5 · Cited by 593
Aging and bone loss: new insights for the clinician
Demontiero, O., Vidal, C., & Duque, G. (2011) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x11430858 · Cited by 602
Osteoporosis: burden, health care provision and opportunities in the EU
Ström, O., Borgström, F., Kanis, J. А., Compston, J. E., Cooper, C. C., McCloskey, E. V., & Jönsson, B. (2011) · Archives of Osteoporosis · doi:10.1007/s11657-011-0060-1 · Cited by 569
Long-Term Use of Bisphosphonates in Osteoporosis
Watts, N. B., & Diab, D. L. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1947 · Cited by 548
The role of DXA bone density scans in the diagnosis and treatment of osteoporosis
Blake, G. M., & Fogelman, I. (2007) · Postgraduate Medical Journal · doi:10.1136/pgmj.2007.057505 · Cited by 532
MacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M., Mojica, W., Timmer, M., Alexander, A., McNamara, M., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-3-200802050-00198 · Cited by 529
Silverman, S. L., Christiansen, C., Genant, H. K., Vukičević, S., Zanchetta, J., de Villiers, T. J., Constantine, G. D., & Chines, A. A. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080710 · Cited by 510
Self-citationBisphosphonates: Mode of Action and Pharmacology
Russell, R. G. G. (2007) · PEDIATRICS · doi:10.1542/peds.2006-2023h · Cited by 513
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.gl · Cited by 491
(2021) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001831 · Cited by 481
Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday
McClung, M. R., Harris, S. T., Miller, P. D., Bauer, D. C., Davison, K. S., Dian, L., Hanley, D. A., Kendler, D. L., Yuen, C. K., & Lewiecki, E. M. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.06.023 · Cited by 460
Watts, N. B., Bilezikian, J. P., Camacho, P. M., Greenspan, S. L., Harris, S. T., Hodgson, S. F., Kleerekoper, M., Luckey, M. M., McClung, M. R., Pessah‐Pollack, R., et al. (2010) · Endocrine Practice · doi:10.4158/ep.16.s3.1 · Cited by 442
Perazella, M. A., & Markowitz, G. S. (2008) · Kidney International · doi:10.1038/ki.2008.356 · Cited by 424
Russell, R. G. G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.041 · Cited by 416
Ettinger, B. B., Harris, S. T., Kendler, D. L., Kessel, B., McClung, M. R., Gorodeski, G. I., Rothert, M. L., Henderson, V. W., Richardson, M. K., Freedman, R. R., et al. (2006) · Cited by 403
Adverse effects of bisphosphonates: Implications for osteoporosis management
Kennel, K. A., & Drake, M. T. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60752-0 · Cited by 496
Russell, R. G. G., Xia, Z., Dunford, J. E., Oppermann, U. C. T., Kwaasi, A. A. A., Hulley, P. A., Kavanagh, K. L., Triffitt, J. T., Lundy, M. W., Phipps, R. J., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.089 · Cited by 407
Management of osteoporosis in postmenopausal women
(2010) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181c617e6 · Cited by 390
The Assessment of Fracture Risk
Unnanuntana, A., Gladnick, B. P., Donnelly, E. L., & Lane, J. M. (2010) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.i.00919 · Cited by 378
Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials
Bouxsein, M., Eastell, R., Lui, L., Wu, L., de Papp, A. E., Grauer, A., Marín, F., Cauley, J. A., Bauer, D. C., Black, D. M., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3641 · Cited by 357
Bone Morphogenetic Protein-2 in Development and Bone Homeostasis
Halloran, D., Durbano, H. W., & Nohe, A. (2020) · Journal of Developmental Biology · doi:10.3390/jdb8030019 · Cited by 348
Miller, P. D., Mcclung, M. R., Macovei, L., Stakkestad, J. A., Luckey, M., Bonvoisin, B., Reginster, J.-Y., Recker, R. R., Hughes, C., Lewiecki, E. M., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050313 · Cited by 333
Self-citationEffect of Osteoporosis Treatment on Mortality: A Meta-Analysis
Bolland, M. J., Grey, A. B., Gamble, G. D., & Reid, I. R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0852 · Cited by 335
Reginster, J.-Y., Adami, S., Lakatos, P., Greenwald, M., Stepan, J. J., Silverman, S. L., Christiansen, C., Rowell, L., Mairon, N., Bonvoisin, B., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044958 · Cited by 326
Self-citationBenefits and risks of bisphosphonate therapy for osteoporosis
Khosla, S., Bilezikian, J. P., Dempster, D. W., Lewiecki, E. M., Miller, P. D., Neer, R. M., Recker, R. R., Shane, E., Shoback, D., & Potts, J. T. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1027 · Cited by 290
Ayers, C. K., Kansagara, D. L., Lazur, B. H., Fu, R. F., Kwon, A., & Harrod, C. S. (2023) · Annals of Internal Medicine · doi:10.7326/m22-0684 · Cited by 297
Leder, B. Z., Tsai, J. N., Uihlein, A. V., Burnett‐Bowie, S. M., Zhu, Y., Foley, K., Lee, H., & Neer, R. M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4440 · Cited by 283
Long-term and sequential treatment for osteoporosis
Foessl, I., Dimai, H. P., & Obermayer-Pietsch, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00866-9 · Cited by 273
Delmas, P. D., Adami, S., Strugała, C., Stakkestad, J. A., Reginster, J., Felsenberg, D., Christiansen, C., Civitelli, R., Drezner, M. K., Recker, R. R., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21918 · Cited by 258
Self-citationOsteoporosis: Pathophysiology and therapeutic options
Föger‐Samwald, U., Dovjak, P., Azizi-Semrad, U., Kerschan‐Schindl, K., & Pietschmann, P. (2020) · EXCLI journal · doi:10.17179/excli2020-2591 · Cited by 284
Black, D. M., Reid, I. R., Cauley, J. A., Cosman, F., Leung, P., Lakatos, P., Lippuner, K., Cummings, S. R., Hue, T. F., Mukhopadhyay, A., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2442 · Cited by 260
Rosen, C. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp043801 · Cited by 254
Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis
Cosman, F., Nieves, J. W., & Dempster, D. W. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3051 · Cited by 253
Recker, R. R., Gallagher, R., & MacCosbe, P. E. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.7.856 · Cited by 250
Self-citationFalls and Fractures: A systematic approach to screening and prevention
Ambrose, A. F., Cruz, L. C., & Paul, G. (2015) · Maturitas · doi:10.1016/j.maturitas.2015.06.035 · Cited by 247
Rizzoli, R., Åkesson, K., Bouxsein, M., Kanis, J. A., Napoli, N., Papapoulos, S. E., Reginster, J.-Y., & Cooper, C. C. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1453-5 · Cited by 244
The challenges of diagnosing osteoporosis and the limitations of currently available tools
Choksi, P. U., Jepsen, K. J., & Clines, G. A. (2018) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-018-0062-7 · Cited by 249
Morin, S. N., Leslie, W. D., & Schousboe, J. T. (2025) · JAMA · doi:10.1001/jama.2025.6003 · Cited by 284
Bone Loss and Fracture Risk Associated with Cancer Therapy
Guise, T. A. (2006) · The Oncologist · doi:10.1634/theoncologist.11-10-1121 · Cited by 250
Black, D. M., Bauer, D. C., Vittinghoff, E., Lui, L.-Y., Grauer, A., Marin, F., Khosla, S., de Papp, A., Mitlak, B., Cauley, J. A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30159-5 · Cited by 228
Pharmacokinetics/Pharmacodynamics of Bisphosphonates
Cremers, S. C. L. M., Pillai, G. C., & Papapoulos, S. E. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544060-00001 · Cited by 246
Update on Osteoporosis Screening and Management
Anam, A. K., & Insogna, K. L. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.05.016 · Cited by 244
Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women
Rabenda, V., Mertens, R., Fabri, V., Vanoverloop, J., Sumkay, F., Vannecke, C., Deswaef, A., Verpooten, G. A., & Reginster, J. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0506-x · Cited by 226
Discovery, Clinical Development, and Therapeutic Uses of Bisphosphonates
Licata, A. A. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e357 · Cited by 222
Händel, M. N., Cardoso, I., von Bülow, C., Rohde, J. F., Ussing, A., Nielsen, S. M., Christensen, R., Body, J., Brandi, M. L., Díez‐Pérez, A., et al. (2023) · BMJ · doi:10.1136/bmj-2021-068033 · Cited by 236
Salmon calcitonin: a review of current and future therapeutic indications
Chesnut, C. H., Azria, M., Silverman, S., Engelhardt, M., Olson, M., & Mindeholm, L. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0490-1 · Cited by 216
Self-citationSzulc, P., & Delmas, P. D. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0660-9 · Cited by 218
Self-citationThe epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil
Baccaro, L. F., Conde, D. M., Costa‐Paiva, L., & Pinto-Neto, A. M. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s54614 · Cited by 222
Screening for Osteoporosis: An Update for the U.S. Preventive Services Task Force
Nelson, H. D., Haney, E. M., Dana, T., Bougatsos, C., & Chou, R. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-2-201007200-00262 · Cited by 214
Vertebral Fracture Assessment: The 2007 ISCD Official Positions
Schousboe, J. T., Vokes, T., Broy, S. B., Ferrar, L., McKiernan, F., Roux, C., & Binkley, N. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2007.12.008 · Cited by 214
Bisphosphonates for Osteoporosis
Favus, M. J. (2010) · New England Journal of Medicine · doi:10.1056/nejmct1004903 · Cited by 211
Antiresorptive therapies for osteoporosis: a clinical overview
Chen, J. S., & Sambrook, P. N. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.146 · Cited by 213
Overview of treatment approaches to osteoporosis
Langdahl, B. L. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15024 · Cited by 222
Lupsa, B. C., & Insogna, K. L. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.05.002 · Cited by 222
Rizzoli, R., Reginster, J., Boonen, S., Bréart, G., Díez‐Pérez, A., Felsenberg, D., Kaufman, J., Kanis, J. А., & Cooper, C. C. (2011) · Calcified Tissue International · doi:10.1007/s00223-011-9499-8 · Cited by 208
Self-citationTreating osteoporosis to prevent fractures: current concepts and future developments
Lorentzon, M. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12873 · Cited by 211
Clinical Applications of Vertebral Fracture Assessment by Dual-Energy X-Ray Absorptiometry
Lewiecki, E. M., & Laster, A. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1178 · Cited by 201
Eriksen, E. F., Díez‐Pérez, A., & Boonen, S. (2013) · Bone · doi:10.1016/j.bone.2013.09.023 · Cited by 201
Lester, J., Dodwell, D. J., Purohit, O. P., Gutcher, S. A., Ellis, S. P., Thorpe, R., Horsman, J. M., Brown, J. E., Hannon, R. A., & Coleman, R. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5101 · Cited by 188
Biomedical applications of bisphosphonates
Giger, E. V., Castagner, B., & Leroux, J. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.01.032 · Cited by 192
Epidemiology and management of osteoporosis in the People’s Republic of China: current perspectives
Yuan, L., Lin, X., Xiong, D., Peng, Y., Sheng, Z., Wu, X.-P., Wu, F., Liao, E.-Y., & Wu, X. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s54613 · Cited by 185
Management of osteoporosis in postmenopausal women
(2006) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000222475.93345.b3 · Cited by 185
2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis
Briot, K., Cortet, B., Thomas, T., Audran, M., Blain, H., Breuil, V., Chapuis, L., Chapurlat, R. D., Fardellone, P., Féron, J.-M., et al. (2012) · Joint Bone Spine · doi:10.1016/j.jbspin.2012.02.014 · Cited by 191
Migliorini, F., Maffulli, N., Colarossi, G., Eschweiler, J., Tingart, M., & Betsch, M. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-021-02678-x · Cited by 184
Qaseem, A., Snow, V., Shekelle, P., Hopkins, R., Forciea, M. A., Owens, D. K., & Clinical Efficacy Assessment Subcommittee of the American College of Physicians (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-6-200809160-00007 · Cited by 180
Bisphosphonates for the prevention and treatment of osteoporosis
Maraka, S., & Kennel, K. A. (2015) · BMJ · doi:10.1136/bmj.h3783 · Cited by 181
Silverman, S. L., Watts, N. B., Delmas, P. D., Lange, J. L., & Lindsay, R. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0274-z · Cited by 176
Self-citationRecker, R. R., Stakkestad, J. A., Chesnut, C. H., Christiansen, C., Skag, A., Høiseth, A. D., Ettinger, M. P., Mahoney, P., Schimmer, R. C., & Delmas, P. D. (2004) · Bone · doi:10.1016/j.bone.2004.01.008 · Cited by 172
Self-citationNaylor, K. E., Jacques, R., Paggiosi, M., Gossiel, F., Peel, N. F. A., McCloskey, E. V., Walsh, J., & Eastell, R. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3145-7 · Cited by 175
Emkey, R. D., Koltun, W. D., Beusterien, K. M., Seidman, L. S., Kivitz, A., Devas, V., & Masanauskaite, D. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x74862 · Cited by 169
Efficacy of Bisphosphonates in Reducing Fracture Risk in Postmenopausal Osteoporosis
Bilezikian, J. P. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.12.003 · Cited by 168
for the Bazedoxifene Study Group, Silverman, S. L., Chines, A. A., Kendler, D. L., Kung, A. W. C., Teglbjærg, C. S., Felsenberg, D., Mairon, N., Constantine, G. D., & Adachi, J. D. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1691-1 · Cited by 165
Self-citationDavis, S., Simpson, E. L., Hamilton, J., James, M. M., Rawdin, A., Wong, R., Goka, E., Gittoes, N. J. L., & Selby, P. L. (2020) · Health Technology Assessment · doi:10.3310/hta24290 · Cited by 170
Watts, N. B., Geusens, P., Barton, I. P., & Felsenberg, D. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050814 · Cited by 163
Self-citationBauer, D. C., Krege, J. H., Lane, N. E., Leary, E., Libanati, C. R., Miller, P. D., Myers, G. L., Silverman, S., Vesper, H. W., Lee, D., et al. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2049-z · Cited by 158
Role of Dual-Energy X-Ray Absorptiometry in the Diagnosis and Treatment of Osteoporosis
Blake, G. M., & Fogelman, I. (2006) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2006.11.001 · Cited by 158
Metadata
- Authors
- Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., Delmas, P. D., & (BONE), F. T. O. I. O. V. F. T. I. N. A. A. E.
- Affiliations
- University of Washington (US)
- Center for Clinical Trials, Bergen, Norway
- Center for Clinical & Basic Research (DK)
- Creighton University (US)
- CECOR AS, Haugesund, Norway
- Oslo Department, Sentrum Røntgen Institut AS, Oslo, Norway
- Universitatsklinikum Benjamin Franklin, Berlin, Germany
- Leverkusen, Germany
- Roche (United Kingdom) (GB)
- F. Hoffmann-La Roche AG (CH)
- Lyon 1 Université (FR)
- Corresponding author
- Chesnut, Charles H
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08-01
- Volume
- 19
- Issue
- 8
- Pages
- 1241-1249
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2099054178
- Cited by
- 1,229
- References
- 42
- Citations by year
- 2026: 14 · 2025: 38 · 2024: 20 · 2023: 42 · 2022: 31 · 2021: 37 · 2020: 35 · 2019: 32 · 2018: 32 · 2017: 31 · 2016: 43 · 2015: 45 · 2014: 45 · 2013: 63 · 2012: 62
- FWCI
- 85.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- F. Hoffmann-La Roche
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- ibandronate, intermittent dosing, bisphosphonates, postmenopausal osteoporosis, vertebral fractures, fracture risk reduction, bone mineral density, bone turnover, height loss, drug safety, medication adherence, lumbar spine, hip bone density, antifracture efficacy, treatment discontinuation, adverse events
- MeSH terms
- Ibandronic Acid, Aged, Body Height, Bone and Bones, Diphosphonates, Double-Blind Method, Female, Femur, Humans, Lumbar Vertebrae, Middle Aged, Pelvic Bones, Prospective Studies, Risk Factors, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Treatment Outcome, Patient Selection, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
